查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1567324

唾液腺感染疾病的全球市场:各类型，各用途，各国，企业的分析(2024年～2032年)

Global Salivary Gland Infection Market Report Global Forecast by Type (Diagnosis, Treatment), Application (Hospital, Clinic, Household, Other) Country and Company Analysis 2024-2032
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

唾液腺感染的市场规模

预计2023年全球唾液腺感染市场规模将达到29.3亿美元，到2032年将达到47.2亿美元，2024年至2032年复合年增长率为5.44%，预计。预计该市场的成长主要是由于疾病模式的变化、环境的变化以及各种唾液腺感染的流行。由于研发和临床试验资金增加而改进的产品开发也是市场扩张的关键驱动力。这个市场主要由诊断和治疗方案的进步、自我保健意识的提高以及卫生习惯的改善所推动。

世界各地唾液腺感染概况

当唾液腺或唾液管被细菌或病毒感染时，就会发生唾液腺感染。唾液流量减少可能是由于唾液管堵塞或发炎引起的，这也可能导致感染。这种疾病称为唾液腺炎。唾液腺感染可以影响任何人，包括婴儿，但老年人和患有长期疾病的人尤其容易受到影响。这种疾病被称为唾液腺炎，其特征是一个或多个唾液腺肿胀和发炎。存在急性和慢性两种形式。唾液腺炎的确切原因尚不清楚。唾液腺结石（唾液腺结石的形成）有时与这种疾病有关。

由于唾液腺炎，一个或多个唾液腺可能会变得肿胀、敏感或发红。唾液腺包括耳朵附近的腮腺、舌下腺和下颔腺，以及舌头、嘴唇、脸颊和上颚上的几个较小的腺体。这些腺体的分泌物可能会被唾液结石或结石阻塞。

有时唾液腺会受到感染，导致发烧和其他症状。急性和慢性唾液腺炎的共同特征是唾液流量减少。用餐时疼痛变得明显，超过 75% 的患者主诉口干（口干症）。其他疾病包括结节病、脱水、营养不良、癌症放射治疗、疱疹、爱滋病毒、A/II 型流感、I/II 型副流感、唾液结石、唾液管黏液阻塞、肿瘤和干燥症候群、结节病和口腔不良。

唾液腺感染市场的成长推动因素

感染率上升

对唾液腺感染替代治疗的需求通常是由传染病的流行所驱动的，特别是细菌、真菌和病毒感染。由于不良的牙齿卫生、生活方式的改变以及对抗生素产生抗药性的细菌的出现，真菌感染、细菌性唾液腺炎和腮腺炎等疾病的盛行率经常上升。此类病例数量的增加表明需要有效的治疗和诊断方法。

随着人们对唾液腺健康重要性的认识不断增加，医疗保健专业人员越来越关注识别和治疗这些感染。由于兴趣的增加，患者越来越早地寻求治疗，对尖端治疗方案的需求也增加。此外，旨在改善患者预后的研究活动的增加和治疗技术的进步增强了市场发展潜力。

唾液腺感染市场概述：各地区

儘管存在各种发展推动因素和障碍，全球唾液腺感染市场在所有地区都在整体成长。随着治疗方案变得更加广为人知和容易获得，该行业预计将会成长。

唾液腺感染公司新闻

2022 年 8 月，澳洲推出了世界上第一个 DNA 筛检计划，以检查癌症和心臟病的风险。该倡议是由澳洲莫纳什大学领导的一项全国性合作计画。

2022 年 6 月，Goodbody Health Inc. 推出了四项新测试，利用基因分析来估计个人 10 年内罹患心臟病和癌症的风险。这些产品的推出预计将加速该领域的未来成长。

本报告提供全球唾液腺感染疾病市场相关调查，提供市场规模与成长率，成长推动因素与课题，各地区市场占有率，主要企业的分析等资讯。

目录

第1章 简介

第2章 调查和调查手法

第3章 摘要整理

第4章 市场动态

  • 成长促进因素
  • 课题

第5章 全球唾液腺感染疾病市场

第6章 全球唾液腺感染疾病的市场占有率的分析

  • 各类型
  • 各用途
  • 各国

第7章 类型 - 全球唾液腺感染疾病市场

  • 诊断
  • 治疗

第8章 用途 - 全球唾液腺感染疾病市场

  • 医院
  • 诊疗所
  • 家庭
  • 其他

第9章 国家- 全球唾液腺感染疾病市场

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 比利时
    • 荷兰
    • 土耳其
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
    • 马来西亚
    • 印尼
    • 纽西兰
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东·非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国

第10章 波特的五力分析

第11章 SWOT分析

第12章 主要企业的分析

  • AbbVie Inc.
  • Allergan plc.
  • AstraZeneca
  • FUJIFILM Holdings Corporation
  • General Electric Company
  • GlaxoSmithKline plc.
  • Merck & Co
  • Pfizer Inc.
  • Siemens Healthcare GmbH
简介目录

Salivary Gland Infection Market Size

The Salivary Gland Infection market is expected to reach US$ 2.93 Billion in 2023 to US$ 4.72 Billion by 2032, with a CAGR of 5.44 % from 2024 to 2032. The market is expected to rise due in large part to changing disease patterns, environmental changes, and the rising prevalence of various salivary gland infections. Improved product development as a result of increased financing for R&D and clinical trials is another important driver of market expansion. The market is mostly driven by advances in diagnosis and treatment choices, more self-care awareness, and improved hygiene practices.

Global Salivary Gland Infection Overview

A salivary gland infection happens when the salivary gland or duct is infected by bacteria or viruses. Reduced saliva flow, which may be brought on by an obstruction or inflammation of the salivary duct, may be the cause of the infection. The illness is known as sialadenitis. While salivary gland infections can strike anybody, including infants, the elderly and those with long-term illnesses are particularly vulnerable to the ailment. The illness known as salivalentitis is typified by swelling and inflammation of one or more salivary glands. Both acute and chronic versions exist. Unknown is the precise cause of sialadenitis. Sialolithiasis, or the production of salivary gland stones, may occasionally be linked to the disorder.

One or more salivary glands may swell, become sensitive, or become red as a result of sialadenitis. These include several tiny glands in the tongue, lips, cheeks, and palate in addition to the mouth's parotid, sublingual, and submaxillary glands, which are situated close to the ear. Any of these glands' secretions may be obstructed by salivary stones, or calculi.

Occasionally, the gland may get infected, resulting in fever and other problems. A characteristic shared by both the acute and chronic forms of sialadenitis is decreased salivary flow. During eating, the pain is more noticeable, and over 75% of patients report having dry mouth (xerostomia). Additional medical conditions include sarcoidosis, dehydration, malnutrition, radiation treatment for cancer, herpes, HIV, influenza A and type II, parainfluenza types I and II, salivary stones, mucus-blocking salivary ducts, tumors, Sjogren's syndrome, sarcoidosis, and inadequate oral hygiene, which can reduce salivary production and cause sialadenitis.

Growth Drivers for the Salivary Gland Infection Market

Rising infection rates

The need for treatment alternatives for salivary gland infections is mostly driven by the rising prevalence of infections, especially bacterial, fungal, and viral infections. The prevalence of illnesses such fungal infections, bacterial sialadenitis, and the mumps is rising, frequently as a result of poor dental hygiene, changing lifestyles, and the emergence of germs resistant to antibiotics. The increase in instances emphasizes the necessity of efficient therapeutic and diagnostic approaches.

Healthcare professionals are becoming more alert in identifying and treating these infections as knowledge of the significance of salivary gland health develops. Patients are encouraged to seek medical attention earlier as a result of this increased focus, which increases demand for cutting-edge treatment choices. Furthermore, the market's development potential is reinforced by the increased research activities and advancements in therapeutic technologies aimed at improving patient outcomes.

Improvements in lifestyle

Changes in lifestyle, such as nutrition and stress levels, have a big effect on dental health and raise the risk of salivary gland infections. Poor dental hygiene can result from diets heavy in sugar and processed foods, which in turn encourages bacterial development and raises the risk of illnesses. Furthermore, problems with the salivary glands can be made worse by dehydration and decreased salivation-both of which are prevalent in people who lead unhealthy lives.

Moreover, it is well recognized that high stress levels impair immune function, leaving people more vulnerable to illnesses. Prolonged stress can cause bad habits like teeth grinding, which can harm salivary gland function. The demand for efficient treatment choices is rising in tandem with the growing knowledge of these lifestyle-related dangers, underscoring the necessity of novel therapeutics to address these health issues.

Salivary Gland Infection Market Overview by Regions

With different development drivers and obstacles, the worldwide market for salivary gland infections is generally rising across all geographies. The industry is expected to develop as long as treatment choices become more widely known and accessible. An overview of the market by region is given below:

North America Salivary Gland Infection Market

United States

The increasing prevalence of illnesses like bacterial sialadenitis and viral infections like mumps has led to a thriving market for salivary gland infections in the US. The availability of efficient diagnostic tools and treatment choices is improved by an advanced healthcare infrastructure and a strong focus on research and innovation. The management of chronic diseases and improved oral health are two areas where early detection and action are aided. Furthermore, an elderly population is more prone to illnesses, which increases demand in the market. Overall, the market for salivary gland infections is expected to rise in the United States due to continual improvements in healthcare.

Europe Salivary Gland Infection Market

Germany

Germany's market for salivary gland infections is steadily expanding due to an older population and rising oral health awareness. There is an increasing need for efficient diagnosis and treatment alternatives due to the rising occurrence of diseases like mumps and sialadenitis. Market expansion is further supported by a concentration on research and development and an advanced healthcare infrastructure. Oral hygiene-related public health efforts improve patient outcomes by facilitating early diagnosis and intervention. Germany is positioned to be a major participant in the European salivary gland infection market as healthcare costs rise.

Asia Pacific Salivary Gland Infection Market

China

China's market for salivary gland infections is expanding significantly due to factors such changing eating patterns, growing urbanization, and growing awareness of oral health. Changes in lifestyle and environmental factors are contributing to an increase in the occurrence of illnesses like sialadenitis. Early infection diagnosis and management are being made easier by advancements in healthcare infrastructure and access to cutting-edge diagnostic and treatment alternatives. Market expansion is further supported by government measures focused at improving public health education. China is emerging as a major participant in the worldwide market for salivary gland infections as the healthcare industry continues to change.

Middle East & Africa Salivary Gland Infection Market

Saudi Arabia

Saudi Arabia's market for salivary gland infections is expanding as a result of improving oral health awareness and the prevalence of illnesses like sialadenitis. Dietary modifications and lifestyle choices are among the factors that increase the likelihood of developing these illnesses. The government's emphasis on enhancing access to specialized services and the infrastructure supporting healthcare improves diagnosis and treatment options. Furthermore, oral hygiene education programs run by public health organizations are essential for early detection and prevention. Saudi Arabia is establishing itself as an emerging market in the field of salivary gland infections as medical technology advances.

Salivary Gland Infection Company Analysis

The major participants in the Salivary Gland Infection market includes AbbVie Inc., Allergan plc., AstraZeneca, FUJIFILM Holdings Corporation, General Electric Company, GlaxoSmithKline plc., Merck & Co, Pfizer Inc., Siemens Healthcare GmbH.

Salivary Gland Infection Company News

In August 2022, t One of the world's first DNA screening programs for cancer and heart disease risk was introduced in Australia with free salivary DNA tests. The initiative is a national collaboration headed by Monash University in Australia.

In June 2022, Goodbody Health Inc. has introduced four new tests that use genetic analysis to estimate an individual's 10-year risk of developing heart disease or cancer. It is anticipated that these launches would accelerate this segment's future growth.

Types- Industry is divided into 2 viewpoints:

1. Diagnosis

2. Treatment

Application- Industry is divided into 4 viewpoints:

1. Hospital

2. Clinic

3. Household

4. Other

Countries- Industry is divided into 25 viewpoints:

North America

  • United States
  • Canada

Europe

  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Belgium
  • Netherlands
  • Turkey

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • New Zealand

Latin America

  • Brazil
  • Mexico
  • Argentina

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • United Arab Emirates

All companies have been covered with 5 Viewpoints

1. Overviews

2. Key Person

3. Recent Developments & Strategies

4. Product Portfolio & Product Launch in Last 1 Year

5. Revenue

Company Analysis

1. AbbVie Inc.

2. Allergan plc.

3. AstraZeneca

4. FUJIFILM Holdings Corporation

5. General Electric Company

6. GlaxoSmithKline plc.

7. Merck & Co

8. Pfizer Inc.

9. Siemens Healthcare GmbH

Key Questions Answered in Report:

1. How big is the Salivary Gland Infection industry?

2. What is the Salivary Gland Infection growth rate?

3. Who are the key players in Salivary Gland Infection industry?

4. What are the factors driving the Salivary Gland Infection industry?

5. Which Region held the largest market share in the Salivary Gland Infection industry?

6. What segments are covered in the Salivary Gland Infection Market report?

Table of Contents

1. Introductions

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Driver
  • 4.2 Challenges

5. Global Salivary Gland Infection Market

6. Global Salivary Gland Infection Market Share Analysis

  • 6.1 By Types
  • 6.2 By Application
  • 6.3 By Country

7. Types - Global Salivary Gland Infection Market

  • 7.1 Diagnosis
  • 7.2 Treatment

8. Application - Global Salivary Gland Infection Market

  • 8.1 Hospital
  • 8.2 Clinic
  • 8.3 Household
  • 8.4 Other

9. Country - Global Industrial Hemp Market

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
  • 9.2 Europe
    • 9.2.1 France
    • 9.2.2 Germany
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Belgium
    • 9.2.7 Netherlands
    • 9.2.8 Turkey
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 South Korea
    • 9.3.6 Thailand
    • 9.3.7 Malaysia
    • 9.3.8 Indonesia
    • 9.3.9 New Zealand
  • 9.4 Latin America
    • 9.4.1 Brazil
    • 9.4.2 Mexico
    • 9.4.3 Argentina
  • 9.5 Middle East & Africa
    • 9.5.1 South Africa
    • 9.5.2 Saudi Arabia
    • 9.5.3 United Arab Emirates

10. Porter's Five Forces

  • 10.1 Bargaining Power of Buyers
  • 10.2 Bargaining Power of Suppliers
  • 10.3 Degree of Rivalry
  • 10.4 Threat of New Entrants
  • 10.5 Threat of Substitutes

11. SWOT Analysis

  • 11.1 Strength
  • 11.2 Weakness
  • 11.3 Opportunity
  • 11.4 Threat

12. Key Players Analysis

  • 12.1 AbbVie Inc.
    • 12.1.1 Overviews
    • 12.1.2 Key Person
    • 12.1.3 Recent Developments & Strategies
    • 12.1.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.1.5 Revenue
  • 12.2 Allergan plc.
    • 12.2.1 Overviews
    • 12.2.2 Key Person
    • 12.2.3 Recent Developments & Strategies
    • 12.2.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.2.5 Revenue
  • 12.3 AstraZeneca
    • 12.3.1 Overviews
    • 12.3.2 Key Person
    • 12.3.3 Recent Developments & Strategies
    • 12.3.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.3.5 Revenue
  • 12.4 FUJIFILM Holdings Corporation
    • 12.4.1 Overviews
    • 12.4.2 Key Person
    • 12.4.3 Recent Developments & Strategies
    • 12.4.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.4.5 Revenue
  • 12.5 General Electric Company
    • 12.5.1 Overviews
    • 12.5.2 Key Person
    • 12.5.3 Recent Developments & Strategies
    • 12.5.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.5.5 Revenue
  • 12.6 GlaxoSmithKline plc.
    • 12.6.1 Overviews
    • 12.6.2 Key Person
    • 12.6.3 Recent Developments & Strategies
    • 12.6.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.6.5 Revenue
  • 12.7 Merck & Co
    • 12.7.1 Overviews
    • 12.7.2 Key Person
    • 12.7.3 Recent Developments & Strategies
    • 12.7.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.7.5 Revenue
  • 12.8 Pfizer Inc.
    • 12.8.1 Overviews
    • 12.8.2 Key Person
    • 12.8.3 Recent Developments & Strategies
    • 12.8.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.8.5 Revenue
  • 12.9 Siemens Healthcare GmbH
    • 12.9.1 Overviews
    • 12.9.2 Key Person
    • 12.9.3 Recent Developments & Strategies
    • 12.9.4 Product Portfolio & Product Launch in Last 1 Year
    • 12.9.5 Revenue